Tissue Clock Beyond Time Clock: Endovascular Thrombectomy for Patients With Large Vessel Occlusion Stroke Beyond 24 Hours.

Delayed treatment Ischemic stroke Thrombectomy

Journal

Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023

Informations de publication

Date de publication:
May 2023
Historique:
received: 02 01 2023
accepted: 10 03 2023
medline: 7 6 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

Randomized trials proved the benefits of mechanical thrombectomy (MT) for select patients with large vessel occlusion (LVO) within 24 hours of last-known-well (LKW). Recent data suggest that LVO patients may benefit from MT beyond 24 hours. This study reports the safety and outcomes of MT beyond 24 hours of LKW compared to standard medical therapy (SMT). This is a retrospective analysis of LVO patients presented to 11 comprehensive stroke centers in the United States beyond 24 hours from LKW between January 2015 and December 2021. We assessed 90-day outcomes using the modified Rankin Scale (mRS). Of 334 patients presented with LVO beyond 24 hours, 64% received MT and 36% received SMT only. Patients who received MT were older (67±15 vs. 64±15 years, P=0.047) and had a higher baseline National Institutes of Health Stroke Scale (NIHSS; 16±7 vs.10±9, P<0.001). Successful recanalization (modified thrombolysis in cerebral infarction score 2b-3) was achieved in 83%, and 5.6% had symptomatic intracranial hemorrhage compared to 2.5% in the SMT group (P=0.19). MT was associated with mRS 0-2 at 90 days (adjusted odds ratio [aOR] 5.73, P=0.026), less mortality (34% vs. 63%, P<0.001), and better discharge NIHSS (P<0.001) compared to SMT in patients with baseline NIHSS ≥6. This treatment benefit remained after matching both groups. Age (aOR 0.94, P<0.001), baseline NIHSS (aOR 0.91, P=0.017), Alberta Stroke Program Early Computed Tomography (ASPECTS) score ≥8 (aOR 3.06, P=0.041), and collaterals scores (aOR 1.41, P=0.027) were associated with 90-day functional independence. In patients with salvageable brain tissue, MT for LVO beyond 24 hours appears to improve outcomes compared to SMT, especially in patients with severe strokes. Patients' age, ASPECTS, collaterals, and baseline NIHSS score should be considered before discounting MT merely based on LKW.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Randomized trials proved the benefits of mechanical thrombectomy (MT) for select patients with large vessel occlusion (LVO) within 24 hours of last-known-well (LKW). Recent data suggest that LVO patients may benefit from MT beyond 24 hours. This study reports the safety and outcomes of MT beyond 24 hours of LKW compared to standard medical therapy (SMT).
METHODS METHODS
This is a retrospective analysis of LVO patients presented to 11 comprehensive stroke centers in the United States beyond 24 hours from LKW between January 2015 and December 2021. We assessed 90-day outcomes using the modified Rankin Scale (mRS).
RESULTS RESULTS
Of 334 patients presented with LVO beyond 24 hours, 64% received MT and 36% received SMT only. Patients who received MT were older (67±15 vs. 64±15 years, P=0.047) and had a higher baseline National Institutes of Health Stroke Scale (NIHSS; 16±7 vs.10±9, P<0.001). Successful recanalization (modified thrombolysis in cerebral infarction score 2b-3) was achieved in 83%, and 5.6% had symptomatic intracranial hemorrhage compared to 2.5% in the SMT group (P=0.19). MT was associated with mRS 0-2 at 90 days (adjusted odds ratio [aOR] 5.73, P=0.026), less mortality (34% vs. 63%, P<0.001), and better discharge NIHSS (P<0.001) compared to SMT in patients with baseline NIHSS ≥6. This treatment benefit remained after matching both groups. Age (aOR 0.94, P<0.001), baseline NIHSS (aOR 0.91, P=0.017), Alberta Stroke Program Early Computed Tomography (ASPECTS) score ≥8 (aOR 3.06, P=0.041), and collaterals scores (aOR 1.41, P=0.027) were associated with 90-day functional independence.
CONCLUSION CONCLUSIONS
In patients with salvageable brain tissue, MT for LVO beyond 24 hours appears to improve outcomes compared to SMT, especially in patients with severe strokes. Patients' age, ASPECTS, collaterals, and baseline NIHSS score should be considered before discounting MT merely based on LKW.

Identifiants

pubmed: 37282375
pii: jos.2023.00017
doi: 10.5853/jos.2023.00017
pmc: PMC10250878
doi:

Types de publication

Journal Article

Langues

eng

Pagination

282-290

Références

N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Lancet. 2007 Jan 27;369(9558):275-82
pubmed: 17258667
Stroke. 2018 Oct;49(10):2398-2405
pubmed: 30355094
JAMA Neurol. 2023 Feb 1;80(2):172-182
pubmed: 36574257
J Stroke. 2020 May;22(2):234-244
pubmed: 32635687
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1152-1157
pubmed: 34117100
Ann Neurol. 1983 Sep;14(3):294-301
pubmed: 6314871
AJNR Am J Neuroradiol. 2012 Aug;33(7):1331-6
pubmed: 22383238
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Ther Adv Neurol Disord. 2022 May 25;15:17562864221101083
pubmed: 35646160
J Stroke. 2018 May;20(2):277-279
pubmed: 29886718
Stroke. 2017 Sep;48(9):2621-2627
pubmed: 28794271
J Neurointerv Surg. 2023 Mar;15(3):233-237
pubmed: 35169031
JAMA Neurol. 2021 Sep 1;78(9):1064-1071
pubmed: 34309619
J Neurointerv Surg. 2017 Oct;9(10):917-921
pubmed: 27589861
Stroke. 2010 Sep;41(9):1996-2000
pubmed: 20651271
J Neurointerv Surg. 2018 Nov;10(11):1039-1042
pubmed: 29807887
JAMA Neurol. 2022 Jan 1;79(1):22-31
pubmed: 34747975
Stroke. 2020 Mar;51(3):1014-1016
pubmed: 31847752
Exp Ther Med. 2021 Sep;22(3):954
pubmed: 34335896
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
J Neurointerv Surg. 2021 Feb;13(2):146-151
pubmed: 33028674
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
JAMA Neurol. 2020 Jan 1;77(1):16-24
pubmed: 31545353
Cerebrovasc Dis. 2017;44(5-6):277-284
pubmed: 28877524
Stroke. 2019 Dec;50(12):3360-3368
pubmed: 31658903

Auteurs

Ghada A Mohamed (GA)

Department of Neurology, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Raul G Nogueira (RG)

Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Muhammed Amir Essibayi (MA)

Department of Neurosurgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Hassan Aboul-Nour (H)

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

Mahmoud Mohammaden (M)

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

Diogo C Haussen (DC)

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

Aldo Mendez Ruiz (AM)

Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Bradley A Gross (BA)

Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Okkes Kuybu (O)

Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Mohamed M Salem (MM)

Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, PA, USA.

Jan-Karl Burkhardt (JK)

Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, PA, USA.

Brian Jankowitz (B)

Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, PA, USA.

James E Siegler (JE)

Department of Neurology, Cooper University Medical Center, Camden, NJ, USA.

Pratit Patel (P)

Department of Neurology, Cooper University Medical Center, Camden, NJ, USA.

Taryn Hester (T)

Department of Neurology, Cooper University Medical Center, Camden, NJ, USA.

Santiago Ortega-Gutierrez (S)

Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Mudassir Farooqui (M)

Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Milagros Galecio-Castillo (M)

Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Thanh N Nguyen (TN)

Departments of Neurology and Radiology, Boston University School of Medicine, Boston, MA, USA.

Mohamad Abdalkader (M)

Departments of Neurology and Radiology, Boston University School of Medicine, Boston, MA, USA.

Piers Klein (P)

Departments of Neurology and Radiology, Boston University School of Medicine, Boston, MA, USA.

Jude H Charles (JH)

Departments of Neurology and Radiology, Boston University School of Medicine, Boston, MA, USA.

Vasu Saini (V)

Department of Neurology, University of Miami, Miami, FL, USA.

Dileep R Yavagal (DR)

Department of Neurology, University of Miami, Miami, FL, USA.

Ammar Jumah (A)

Department of Neurology, Henry Ford Health, Detroit, MI, USA.

Ali Alaraj (A)

Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA.

Sophia Peng (S)

Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA.

Muhammad Hafeez (M)

Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA.

Omar Tanweer (O)

Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA.

Peter Kan (P)

Department of Neurosurgery, Baylor School of Medicine, Houston, TX, USA.

Jacopo Scaggiante (J)

Department of Neurosurgery, Baylor School of Medicine, Houston, TX, USA.

Stavros Matsoukas (S)

Department of Neurosurgery, Baylor School of Medicine, Houston, TX, USA.

Johanna T Fifi (JT)

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, NYC, NY, USA.

Stephan A Mayer (SA)

Departments of Neurology and Neurosurgery, Westchester Medical Center, Westchester, NY, USA.

Alex B Chebl (AB)

Department of Neurology, Henry Ford Health, Detroit, MI, USA.

Classifications MeSH